Comparative Pharmacology
Head-to-head clinical analysis: DENDRID versus LIVTENCITY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DENDRID versus LIVTENCITY.
DENDRID vs LIVTENCITY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dendrid (idoxuridine) is a pyrimidine nucleoside analog that inhibits viral DNA replication by incorporating into viral DNA and inhibiting thymidylate synthetase, thereby blocking DNA synthesis.
LIVTENCITY (maribavir) is an inhibitor of the human cytomegalovirus (CMV) UL97 protein kinase, which is essential for viral DNA replication, encapsidation, and egress of mature virions from the infected cell. By blocking UL97 kinase activity, maribavir inhibits viral replication.
1.5 mg/kg IV every 8 hours; typical adult dose 100 mg IV every 8 hours.
200 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged in renal impairment
Terminal elimination half-life is approximately 20 hours, supporting once-daily dosing for sustained antiviral activity.
Primarily renal excretion; unchanged drug accounts for 70-90% of elimination; minor biliary/fecal excretion (<10%)
Primarily hepatobiliary excretion; unchanged drug and metabolites eliminated in feces (86%) and urine (14%).
Category C
Category C
Antiviral
Antiviral